Merck's View On The Challenges Of Ebola Vaccination In The DRC
Executive Summary
With the latest Ebola outbreak threatening to spread across the Democratic Republic of Congo and beyond, efforts are being stepped up to vaccinate the at-risk population and health workers with Merck Sharp & Dohme’s experimental vaccine, V920. MSD’s Mel Kohn spoke to the Pink Sheet about the development of the vaccine, the experience gained from its use to date, and the difficulties involved in getting the vaccine to those who need it.
You may also be interested in...
Coronavirus Vaccine: How Hard Might Development Get? Look At Chikungunya
Epidemiology complicates field efficacy trials, but US FDA advisory committee members regretfully agree that data from non-human primate passive transfer studies is compelling but potentially insufficient for chikungunya vaccines.
Keeping Track Of The US FDA's Final Novel Approvals, CRLs Of 2019
The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.
Merck's Ebola Vaccine Will Get US FDA Decision Before March Review Deadline
Staffer says agency will make a licensure decision "well ahead" of the March action date; 230,000 have received the vaccine under compassionate use.